Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
There is a high incidence among the first degree relatives of the carcinoid patients, indicating the involvement of genetic components in its initiation and pathogenesis.
| Condition |
|---|
|
Carcinoid Neuroendocrine Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | A Pilot Study to Investigate Germ-Line MEN1 and SDHD Gene Mutation in Familial Cases of Carcinoid Cancer |
- Mutations in MEN1 and SDHD genes [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood: a small sample of 2 tubes (2 - 4 teaspoons, or 20 ml). One tube will be used to prepare the DNA (your genetic material) for the test. The other would be used for further gene evaluation. The DNA will be stored with Rutgers University Cell and DNA Repository (RUCDR).
| Estimated Enrollment: | 25 |
| Study Start Date: | April 2008 |
| Estimated Study Completion Date: | June 2010 |
| Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
Families with carcinoid in multiple family members
|
Detailed Description:
This proposed pilot study will conduct detailed interviews into the medical, environmental, and family histories and to collect blood specimen to obtain DNA. The Blood specimen and DNA will be processed by the Rutgers University Cell and DNA Repository (RUCDR) to rule out Familial Multiple Endocrine Neoplasia (MEN 1), and succinate dehydrogenase complex, subunit D (SDHD), gene inactivation thought to be associated with different types of carcinoid cancer.
Eligibility| Ages Eligible for Study: | 12 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Individuals with carcinoid cancer that report to have a first-degree family member also with carcinoid tumor
Inclusion Criteria:
- Over the age of 18 years
- More than one ,member of a family with a history of biopsy confirmed carcinoid tumor
- English speaking
- Mentally and emotionally capable of answering questions
- Willing and available for study participation
- At least one other family member with carcinoid tumor
Exclusion Criteria:
- If you are under the age of 18 years,
- If you are unable to understand or unable to provide informed consent,
- If you have a psychological condition (i.e. depression, anxiety disorder, substance abuse, etc.) which might cause you significant problems in dealing with test results.
Contacts and Locations| Contact: Nancy Gardner, PhD | 813-731-0894 | gardnern@rutgers.edu |
| Contact: Changshun Shao, PhD | Shao@Biology.Rutgers.Edu |
| United States, New Jersey | |
| Busch Campus of Rutgers University, Human Genetics Institute | Recruiting |
| Piscataway, New Jersey, United States, 08854-8082 | |
| Contact: Changshun Shao, PhD 732-445-5406 shao@biology.rutgers.edu | |
| Contact: Nancy Gardner, PhD 973-991-1302 gardnern@rutgers.edu | |
| Principal Investigator: Changshun Shao, PhD | |
| Principal Investigator: Nancy Gardner, PhD | |
| Principal Investigator: | Nancy Gardner, PhD | Rutgers University |
| Principal Investigator: | Changshun Shao, PhD | Rutgers University |
More Information
No publications provided
| Responsible Party: | Nancy Gardner PhD Principal Investigator, Rutgers University |
| ClinicalTrials.gov Identifier: | NCT00672269 History of Changes |
| Other Study ID Numbers: | 08-451 |
| Study First Received: | May 2, 2008 |
| Last Updated: | February 3, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Rutgers University:
|
carcinoid family members familial tumors cancer |
Additional relevant MeSH terms:
|
Carcinoid Tumor Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type |
Neoplasms Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue |
ClinicalTrials.gov processed this record on May 22, 2013